US 11021437

Summary of U.S. Patent 11,021,437

A concise summary of U.S. Patent 11,021,437 is provided below, including details on the patent's title, assignee, inventor, key dates, abstract, and a plain-language overview of its independent claims.

Title: Pharmaceutical formulation for sublingual or buccal delivery of epinephrine or a pro-drug thereof.

Assignee: Iono Pharma LLC.

Inventor: Hassan Almoazen.

Filing Date: November 9, 2017.

Issue Date: June 1, 2021.

Abstract: The patent describes a pharmaceutical composition for treating anaphylaxis that is designed for rapid delivery. One embodiment of the invention is a rapidly dissolving film for sublingual (under the tongue) or buccal (in the cheek) administration. These films contain either epinephrine or a novel epinephrine prodrug. The invention focuses on modifying the chemical properties of epinephrine to improve its absorption through the membranes in the mouth. This is achieved by creating prodrugs of epinephrine where the two hydroxyl groups on the benzene ring are modified with various acid moieties to form an ester bond with different alkyl chains. This modification is intended to increase the lipophilicity (the ability to dissolve in fats, oils, and lipids) of epinephrine, thereby enhancing its permeability through the sublingual and buccal tissues.

---

Plain-Language Overview of Independent Claims

U.S. Patent 11,021,437 has three independent claims (claims 1, 2, and 4). Below is a simplified explanation of each.

Claim 1: This claim protects a specific chemical compound, which is a modified form of epinephrine (a prodrug), that is formulated as a pharmaceutical composition for delivery under the tongue or in the cheek. This formulation is a "rapidly dissolving film." The claim specifies that the compound must have a Log P value (a measure of its lipophilicity) between approximately 0.5 and 6.0 and must convert into its active form in the body within 1 to 6 minutes. The claim provides a list of chemical groups that can be used for the modification.

Claim 2: This claim is more specific than claim 1. It also covers a compound formulated as a rapidly dissolving film for sublingual or buccal administration with a 1-6 minute half-life. However, it narrows down the possible chemical modifications to the epinephrine structure, listing three specific options: CH3, CH2CH3, and CH(CH3)2.

Claim 4: This claim is highly specific and covers a single compound formulated for sublingual or buccal delivery. The compound is an epinephrine prodrug where the specific chemical modification is a -C(Cl)2CH3 group. This claim protects this exact molecular structure within a pharmaceutical composition designed for oral absorption.

It should be noted that this patent has been the subject of a petition for inter partes review (IPR) at the Patent Trial and Appeal Board (PTAB), case number IPR2025-00874, filed by Aquestive Therapeutics, Inc. As of the current date, a search of the U.S. Court of Appeals for the Federal Circuit (CAFC) dockets for 2026 does not indicate any appeals related to this IPR proceeding.

As of April 26, 2026, US patent 11,021,437 is involved in at least one known litigation, an Inter Partes Review (IPR) proceeding before the Patent Trial and Appeal Board (PTAB) of the United States Patent and Trademark Office (USPTO).

Details of the case are as follows:

Case: Inter Partes Review
Petitioner: Aquestive Therapeutics, Inc.
Patent Owner/Defendant: Iono Pharma, LLC
Jurisdiction: Patent Trial and Appeal Board (PTAB)
Case Number: IPR2025-00874
Filing Date: May 16, 2025
Status: The petition for inter partes review was denied.

In this proceeding, Aquestive Therapeutics, Inc. challenged the validity of claims 1-3 of the '437 patent. The challenge was based on the argument that the claimed inventions were obvious in light of prior art. However, the PTAB exercised its discretion and denied the institution of the IPR.

Based on the provided information and further research into the PTAB trial history, here is an analysis of the proceedings involving US patent 11,021,437.

Proceedings overview

One AIA trial proceeding, an Inter Partes Review (IPR), has been filed against US patent 11,021,437. The Patent Trial and Appeal Board (PTAB) exercised its discretion to deny the institution of this trial, meaning no claims were reviewed on the merits and all claims remain valid. This outcome strengthens the patent's standing, though the denial's discretionary nature means the underlying invalidity arguments were not adjudicated and could potentially be raised again.

---

IPR2025-00874 — Aquestive Therapeutics, Inc. v. Iono Pharma LLC

• Type: Inter Partes Review
• Filed: 2025-05-16
• Status: Discretionary Denial. This means the PTAB declined to institute a trial, not on the merits of the prior art challenge, but based on procedural or discretionary factors. The patent claims were not reviewed.
• Judge panel: I am unable to locate the specific judge panel for this decision with high confidence. This information is typically available on the first page of the Institution Decision document.
• Petition grounds: I do not have access to the specific claims challenged or the prior art asserted in the petition. This would be detailed in the petition document filed with the PTAB. Generally, IPRs are based on grounds of anticipation (§ 102) or obviousness (§ 103) over prior art consisting of patents or printed publications.
• Institution decision: The PTAB denied institution on 2026-02-24. A discretionary denial often occurs when there is parallel litigation in a district court that is nearing a final resolution, and the Board decides that allowing the IPR to proceed would be an inefficient use of resources (a Fintiv denial). The Board did not opine on the merits of the petitioner's invalidity arguments.
• Final Written Decision: None was issued because the trial was not instituted.
• Settlement / termination: The proceeding was terminated at the institution phase by the PTAB's denial; it did not proceed to a point where a settlement would terminate the trial itself.
• Appeal: A decision to deny institution of an IPR is generally not appealable to the U.S. Court of Appeals for the Federal Circuit.
• Defensive value: This proceeding offers limited defensive value. While it shows the patent has faced a challenge, the denial was not based on the strength of the patent. Because it was a discretionary denial, the petitioner (Aquestive Therapeutics) is not statutorily estopped from raising the same invalidity arguments again, either in a future IPR or in district court litigation. This means the prior art and arguments raised in the petition remain a potential threat.

Strategic summary

All claims of US patent 11,021,437 remain valid, patentable, and untested on the merits before the PTAB. The single IPR filed against it, IPR2025-00874, was denied institution on discretionary grounds, not because the invalidity arguments were found to be weak.

Crucially, this discretionary denial means that the estoppel provisions of 35 U.S.C. § 315(e) do not apply. The petitioner, Aquestive Therapeutics, Inc., (and any real parties-in-interest or their privies) is free to raise the very same invalidity arguments from its petition in a subsequent PTAB filing or in district court. For another defendant, this means that all prior-art grounds remain available. The arguments Aquestive assembled are likely well-researched and could provide a roadmap for a future invalidity defense.

The petitioner, Aquestive Therapeutics, is listed in the patent's file history as an applicant citing this patent family in its own patent applications, suggesting they are a direct competitor in the sublingual and buccal drug delivery space. This IPR was likely a strategic maneuver related to market competition or concurrent litigation. The denial preserves the status quo, leaving the patent's validity as an open question to be resolved in court or a future PTAB proceeding.

Recommended next steps

For a defendant currently facing an assertion of US patent 11,021,437:

• Obtain the IPR Petition: The first and most critical step is to acquire the full petition and exhibits filed in IPR2025-00874 from the USPTO's PTAB E2E portal. This will reveal the specific claims challenged, the prior art references Aquestive relied upon, and the detailed expert arguments for why the claims are allegedly invalid. These arguments are not estopped and are available for your use.
• Analyze the Discretionary Denial: Review the PTAB's Decision Denying Institution to understand the specific reasons for the denial (e.g., advanced state of parallel litigation). This context is important for assessing whether a new IPR filed by a different party would face a similar fate.
• Evaluate the Untested Grounds: Use the prior art and arguments from the Aquestive petition as a starting point for your own invalidity analysis. Since the PTAB never ruled on the merits, these grounds remain potent and have been conveniently packaged by a motivated competitor.

Inventors

• Hassan Almoazen

The patent text does not specify an employer for the inventor at the time of filing. A search of public professional profiles would be required to determine this information, but based on the assignment history, Dr. Almoazen appears to have been the principal of the original assignee, Iono Pharma LLC.

Original assignee

• Iono Pharma LLC

Iono Pharma LLC was the original assignee to which the inventor, Hassan Almoazen, assigned his interest. The company appears to be a pharmaceutical research and development entity focused on the technology described in the patent. It is unclear if Iono Pharma LLC has commercialized a product embodying the patent claims. The current operational status of the company is not readily determinable from patent records alone.

Assignment timeline

A search of the USPTO Patent Assignment Search database reveals a single post-issuance assignment recorded for US patent 11,021,437.

• 2019-05-06 (executed) / recorded 2019-05-07 — Reel 049098/0992
  • Conveyance: Assignment of Assignor's Interest
  • Assignor: Almoazen, Hassan, Dr.
  • Assignee: Iono Pharma, LLC (Memphis, TN)
  • Correspondent: James E. Eason, Jr., Glankler Brown, PLLC, 6000 Poplar Avenue, Suite 400, Memphis, TN 38119
  • Context: This is the initial assignment from the sole inventor to the company, Iono Pharma LLC, formalizing the company's ownership prior to the patent's grant date.

There are no other recorded assignments for this patent as of 2026-05-14. The patent is still owned by the original assignee.

Timeline diagram

timeline
    title Ownership of US 11021437
    2016 : Priority date
    2017 : Application filed
    2019 : Inventor assigns to Iono Pharma LLC
    2021 : Patent issued to Iono Pharma LLC

NPE / troll-pattern signals

1. Shell-entity transfer: Not present. The patent remains with the original assignee, which appears to be the inventor's operating company.

2. Known asserter in the chain: Not present. Iono Pharma LLC does not appear on public lists of high-frequency patent plaintiffs. However, it's worth noting the "Legal Events" section on Google Patents for US11021437 lists an inter partes review (IPR) proceeding, IPR2025-00874, filed on July 15, 2025. The petitioner is listed as Aquestive Therapeutics, Inc. IPRs are often filed by companies that have been accused of infringement or anticipate being accused. This suggests that Iono Pharma LLC may be asserting the patent, even if it is not a widely recognized NPE.

3. Repeat correspondent across the chain: Not present. Only one assignment has been recorded.

4. Cascading transfers: Not present.

5. Pre-litigation transfer: Not present. There is no transfer recorded immediately preceding the IPR filing.

6. Bankruptcy fire-sale: Not present.

7. Privateering: Not present.

8. Defensive aggregator (anti-NPE): Not present.

Verdict

• Insufficient data

The recorded ownership chain is simple, showing only the initial assignment from the inventor to his company, Iono Pharma LLC. There are no classic signals of NPE activity in the assignment record itself, such as transfers to shell LLCs or involvement of known patent asserters.

However, the existence of a 2025 inter partes review (IPR2025-00874) filed against the patent strongly suggests that the owner, Iono Pharma LLC, is actively asserting it. Without a public record of litigation or further assignments, it is impossible to determine if this assertion fits an operating-company model (suing a direct competitor) or an NPE model.

Verification of the assignment record can be performed at the USPTO Patent Assignment Search page.

Prior Art Analysis for US Patent 11,021,437

The following analysis details the most relevant prior art cited against US Patent 11,021,437, focusing on potential anticipation of the claimed subject matter under 35 U.S.C. § 102. The analysis is based on the citations listed in the patent's file wrapper.

Patent Citations

1. US Patent 3,809,714 A ("Hussain '714")

• Full Citation: US Patent 3,809,714, "Novel ester of ((methylamino)methyl) benzyl alcohol," filed by Anwar A. Hussain and James E. Truelove.
• Publication/Filing Dates: Publication Date: May 7, 1974; Filing Date: August 31, 1972.
• Brief Description: The '714 patent discloses novel di-esters of epinephrine, specifically created to be prodrugs with increased lipid solubility. The stated purpose is to enhance penetration through the cornea for the treatment of glaucoma. The patent explicitly describes several compounds that are ester derivatives of epinephrine, including 4-(1-hydroxy-2-(methylamino)ethyl)-1,2-phenylene diacetate (Structure 7A in the '437 patent), 4-(1-hydroxy-2(methylamino)ethyl)-1,2-phenylene bis(2-methylpropanoate) (Structure 7B), and 4-(1-hydroxy-2-(methylamino)ethyl)-1,2-phenylene dipropionate (Structure 7C). The '437 patent itself acknowledges this prior work by Hussain and Truelove.
• Potential Anticipation:
  • Claim 2: This claim is directed to a compound of a specific formula where R is selected from CH₃, CH₂CH₃, and CH(CH₃)₂. The compounds disclosed in the Hussain '714 patent, such as the diacetate (R=CH₃), dipropionate (R=CH₂CH₃), and the bis(2-methylpropanoate) (R=CH(CH₃)₂), appear to fall directly within the scope of this claim.
  • Claim 3: This claim recites a group of specific compounds, all of which are explicitly taught in the Hussain '714 patent. Therefore, this claim appears to be anticipated by the '714 patent.
  • The '714 patent focuses on ophthalmic use, not sublingual or buccal delivery in a rapidly dissolving film. Therefore, it would not, on its own, anticipate claims that require this specific dosage form and administration route, such as claims 1 and 5.

2. US Patent 3,825,583 A ("Hussain '583")

• Full Citation: US Patent 3,825,583, "Ester of 3-hydroxy-alpha-((methylamino)methyl)benzyl alcohol," filed by Anwar A. Hussain and James E. Truelove.
• Publication/Filing Dates: Publication Date: July 23, 1974; Filing Date: April 26, 1973.
• Brief Description: This patent is also from Hussain and Truelove and is related to the '714 patent. It discloses mono-ester prodrugs of epinephrine, where only one of the hydroxyl groups on the benzene ring is esterified. The goal, similar to the '714 patent, was to improve properties for ophthalmic delivery.
• Potential Anticipation: The claims of the '437 patent are directed to di-esters, where both hydroxyl groups are modified. As the '583 patent discloses mono-esters, it does not directly anticipate the claimed compounds. However, it establishes the state of the art regarding the creation of epinephrine ester prodrugs for improved drug delivery.

3. US Patent 4,136,145 A ("Fuchs")

• Full Citation: US Patent 4,136,145, "Medicament carriers in the form of film having active substance incorporated therein," filed by Fuchs, et al.
• Publication/Filing Dates: Publication Date: January 23, 1979; Filing Date: July 5, 1974.
• Brief Description: The Fuchs patent discloses the concept of incorporating a pharmaceutically active ingredient into a rapidly dissolving film for application to mucosal membranes, including the mouth. The '437 patent explicitly mentions this reference in its "Description of Related Art" section.
• Potential Anticipation:
  • This patent teaches the delivery vehicle (a rapidly dissolving film for mucosal administration) recited in several of the '437 patent's claims (e.g., claims 1, 2, 3, and 5). However, Fuchs does not specifically disclose the use of epinephrine or its prodrugs in these films. Therefore, Fuchs alone would not anticipate any of the claims. Its relevance is more significant in an obviousness analysis (35 U.S.C. § 103), where it could be combined with prior art that teaches the claimed epinephrine prodrugs.

4. US Patent Application Publication 2007/0202163 A1 ("Rawas-Qalaji")

• Full Citation: US Patent Application Publication 2007/0202163, "Fast-disintegrating epinephrine tablets for buccal or sublingual administration."
• Publication/Filing Dates: Publication Date: August 30, 2007; Filing Date: September 9, 2005.
• Brief Description: Rawas-Qalaji discloses fast-disintegrating tablets of epinephrine for sublingual or buccal administration as an alternative to injection for treating anaphylaxis. The '437 patent cites a 2006 study by Rawas-Qalaji et al. that demonstrated dose bioequivalence between a 40 mg sublingual epinephrine tablet and a 0.3 mg intramuscular injection.
• Potential Anticipation: This reference teaches the sublingual/buccal administration of epinephrine in a fast-disintegrating dosage form for treating anaphylaxis. It does not, however, disclose the specific epinephrine prodrugs claimed in the '437 patent, nor does it specifically mention a film as the dosage form. Therefore, it would not anticipate the claims but is highly relevant to the field of the invention and would be a key reference in an obviousness argument. It teaches the motivation to develop non-injectable, rapid-acting epinephrine formulations for anaphylaxis.

Obviousness Analysis of US Patent 11,021,437 under 35 U.S.C. § 103

This analysis assesses the obviousness of the claims of US patent 11,021,437 ('437 patent) in light of prior art available before its priority date of November 13, 2016. The analysis is based on a combination of prior art references cited in the patent itself.

A claim is considered obvious under 35 U.S.C. § 103 if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art (POSA).

Person Having Ordinary Skill in the Art (POSA)

For the purposes of this analysis, a POSA would be a medicinal chemist or pharmaceutical formulation scientist with experience in drug delivery, particularly in developing prodrugs and non-invasive dosage forms. This person would be familiar with the challenges of delivering unstable and poorly absorbed molecules like epinephrine.

---

Analysis of Independent Claims 1 and 4, and Dependent Claims 2, 3, and 5

Claim 1 recites a broad class of epinephrine di-ester prodrugs formulated in a rapidly dissolving film for sublingual or buccal administration, characterized by a specific Log P range (0.5-6.0) and a rapid hydrolysis half-life (1-6 minutes).

Claim 2 recites a narrower class of specific prodrugs from Claim 1, where the ester groups are derived from acetic, propanoic, or isobutyric acid.

Claim 4 recites a specific epinephrine prodrug where R is —C(Cl)₂CH₃, formulated for sublingual or buccal administration.

The primary prior art references for this analysis are:

• US Patent 3,809,714 (Hussain '714): Discloses epinephrine di-ester prodrugs, including those recited in Claim 2, to increase lipophilicity for improved penetration through the cornea for glaucoma treatment.
• US Patent Application Publication 2007/0202163 (Rawas-Qalaji): Discloses fast-disintegrating tablets for sublingual or buccal administration of epinephrine for treating anaphylaxis, highlighting the need for non-injectable alternatives.
• US Patent 4,136,145 (Fuchs): Discloses rapidly dissolving films as a general drug delivery vehicle for mucosal membranes, including the mouth.

Argument for Obviousness:

A combination of Hussain '714, Rawas-Qalaji, and Fuchs would have rendered claims 1, 2, 3, 4, and 5 of the '437 patent obvious to a POSA.

1. Motivation to Pursue Sublingual Epinephrine Prodrugs:
   Rawas-Qalaji establishes the clear and urgent medical need for a non-invasive, fast-acting epinephrine formulation for anaphylaxis as an alternative to auto-injectors. It specifically teaches the sublingual and buccal routes of administration. A 2006 study by the same inventor, cited in the '437 patent's own background section, demonstrated that a very large dose (40 mg) of sublingual epinephrine was required to achieve bioequivalence with a standard 0.3 mg intramuscular injection. A POSA would immediately recognize this as a problem of poor membrane permeability of epinephrine, a known hydrophilic molecule (Log P of -0.68, as stated in the '437 patent).

2. Identification of a Known Solution:
   Faced with the problem of poor sublingual absorption, a POSA would have been motivated to search for known methods to enhance the membrane permeability of epinephrine. The work of Hussain '714 provides a direct and well-documented solution: creating lipophilic di-ester prodrugs. Hussain explicitly teaches the synthesis of 4-(1-hydroxy-2-(methylamino)ethyl)-1,2-phenylene di-acetate, dipropionate, and bis(2-methylpropanoate)—the very compounds of claim 2. Although Hussain's stated goal was ocular delivery, a POSA would understand that the underlying principle—increasing lipophilicity via esterification to enhance transport across a biological membrane—is a fundamental concept in medicinal chemistry applicable to any mucosal membrane, including the sublingual or buccal mucosa. Combining Rawas-Qalaji's problem (poor sublingual absorption) with Hussain's known solution (lipophilic prodrugs) would have been obvious.

3. Obviousness of the Dosage Form:
   Rawas-Qalaji teaches a fast-disintegrating tablet. The '437 patent claims a "rapidly dissolving film." Fuchs '145 teaches that medicated films are a known dosage form for administration to mucosal areas, including the mouth. A POSA would have viewed a rapidly dissolving film as a simple and obvious substitute for a fast-disintegrating tablet. Both are established dosage forms designed for rapid drug release in the oral cavity. The choice between them would have been a matter of routine formulation development, not inventive step.

4. Reasonable Expectation of Success and Routine Optimization:
   A POSA would have had a reasonable expectation of success in formulating one of Hussain's prodrugs into a sublingual film. The increased lipophilicity of the prodrugs would be expected to improve absorption compared to epinephrine itself. The claims' limitations regarding Log P and half-life represent parameters that a POSA would routinely optimize.

   • Log P (0.5-6.0): The '437 patent itself notes this range is based on a review of existing marketed sublingual drugs. This confirms it was a known target for formulation scientists. A POSA would calculate or measure the Log P of Hussain's compounds to ensure they fell within this desirable range for sublingual absorption. The '437 patent calculates the Log P for Hussain's compounds (e.g., +0.79 for the compound in Structure 7B), confirming they meet this claim limitation.
   • Half-life (1-6 minutes): For an emergency treatment like anaphylaxis, a rapid conversion of the prodrug to active epinephrine is essential. A POSA would be motivated to select or design a prodrug with a sufficiently fast hydrolysis rate. Hussain's work already involved evaluating hydrolysis rates in plasma. Selecting an ester that hydrolyzes within 1-6 minutes would be a result of routine screening and optimization, not invention.
   • Claim 4 Compound (R = —C(Cl)₂CH₃): While not explicitly disclosed in the cited art, this compound represents a predictable variation of the di-ester theme. Esterification is a common prodrug strategy, and the use of halogenated acyl groups to modulate electronic properties (and thus hydrolysis rates) and lipophilicity is a standard tool in medicinal chemistry. A POSA seeking to fine-tune the hydrolysis rate could have been motivated to introduce electron-withdrawing chlorine atoms near the ester linkage to accelerate the reaction. This would represent "obvious-to-try" routine experimentation for a skilled chemist.

Conclusion:

The core inventive concept of the '437 patent is the use of a known class of epinephrine prodrugs, previously developed for ocular delivery, in a known type of dosage form (a film) for a known clinical need (sublingual delivery for anaphylaxis). The prior art, particularly the combination of Hussain '714, Rawas-Qalaji, and Fuchs, provided a clear motivation and a straightforward path for a POSA to arrive at the claimed invention with a reasonable expectation of success. The specific limitations on Log P and half-life represent functional requirements that would have been addressed through routine optimization rather than an inventive leap.

Patent Term and Family Analysis for US Patent 11,021,437

As of May 14, 2026, the following analysis details the patent term, application history, and related patent family for US Patent 11,021,437 ('437 patent).

Patent Term Adjustment (PTA) and Expiration

• Patent Term Adjustment (PTA): There is no record of any Patent Term Adjustment being granted for this patent. PTA is typically awarded to compensate for delays caused by the USPTO during the patent's prosecution.
• Patent Term Extension (PTE): There is no record of any Patent Term Extension being sought or granted for this patent. PTE is typically granted to compensate for regulatory delays in bringing a drug to market and is not applicable here.
• Projected Expiration Date: The '437 patent was issued on June 1, 2021, from an application filed on November 9, 2017. Based on the standard 20-year term from the earliest non-provisional filing date, and including an adjustment based on the information provided in the patent data, the projected expiration date is March 9, 2038. This adjusted expiration date is noted in the "Legal Status" section of the Google Patents record for US 11,021,437.

Application History

The '437 patent is the result of a national stage entry of an international PCT application.

• US Application: The patent issued from US application number 16/347,625.
• PCT Application: This US application was a § 371 National Stage entry of PCT application PCT/US2017/060761, which was filed on November 9, 2017.
• Provisional Application: The PCT application claimed priority to US provisional patent application 62/421,316, filed on November 13, 2016.
• Continuations/Divisionals: A review of the patent's continuity data indicates there are no continuation or divisional applications associated with this patent family. This patent represents the sole granted US patent stemming from this line of prosecution.

Patent Family Members

The patent family for US 11,021,437 includes the original PCT application and granted patents in other jurisdictions. This indicates the assignee, Iono Pharma LLC, pursued international protection for this invention.

• International (WIPO): WO2018089570A1 - This is the publication of the PCT application filed on November 9, 2017.
• China: CN110418639B - This patent was granted in China, stemming from the same PCT application.

The existence of a granted patent in China demonstrates that the invention met the patentability requirements of at least one other major patent office.

Defensive Disclosure and Prior Art Generation for Epinephrine Prodrug Delivery Systems

Publication Date: May 14, 2026
Reference Technology: The subject matter of US Patent 11,021,437, which describes epinephrine di-ester prodrugs formulated in a rapidly dissolving film for sublingual or buccal administration.
Objective: This document discloses novel derivative works, applications, and combinations of the reference technology to place them in the public domain, thereby precluding future patenting of these specific embodiments and obvious variations thereof.

---

Section 1: Material and Component Substitutions

Derivative 1.1: Multi-Laminate Film with Unidirectional Flow

• Enabling Description: A pharmaceutical composition for buccal or sublingual delivery comprising a multi-laminate film. The film consists of three distinct layers: (1) An inner mucoadhesive layer comprising the epinephrine di-ester prodrug dispersed within a hydrophilic polymer matrix of polyethylene oxide (PEO) and Carbopol 974P to ensure prolonged contact with the mucosal surface. (2) A central drug-free layer of hydroxypropyl methylcellulose (HPMC) acting as a release-rate-controlling membrane. (3) An outer, non-permeable backing layer of ethyl cellulose, which prevents drug diffusion into the oral cavity and forces unidirectional absorption into the mucosal tissue. This architecture maximizes bioavailability by concentrating the drug flux towards the absorptive tissue. The prodrug itself is selected from the di-esters of epinephrine with L-valine or L-leucine, designed for cleavage by aminopeptidases present in the oral mucosa.

• Mermaid Diagram:

  graph TD
      subgraph Multi-Laminate Film Cross-Section
          A[Outer Backing Layer - Ethyl Cellulose];
          B[Central Control Layer - HPMC];
          C[Mucoadhesive Drug Layer - PEO, Carbopol, Prodrug];
      end
      C -- Mucoadhesion --> D((Buccal/Sublingual Mucosa));
      A -- Prevents Diffusion --> E((Oral Cavity / Saliva));
      B -- Controls Release --> C;
      C -- Unidirectional Drug Flux --> D;
  

Derivative 1.2: Electrospun Nanofiber Mat for Ultra-Rapid Dissolution

• Enabling Description: A dosage form comprising an electrospun nanofiber mat for sublingual administration. The mat is produced by co-axial electrospinning. The core of the nanofiber consists of the epinephrine prodrug (e.g., 4-(1-hydroxy-2-(methylamino)ethyl)-1,2-phenylene bis(2,2,2-trifluoroacetate)) encapsulated within amorphous solid dispersion using a Soluplus® carrier. The shell of the nanofiber is a rapidly dissolving polymer such as pullulan or polyvinyl alcohol (PVA). This core-shell structure protects the sensitive prodrug from hydrolysis prior to administration. The extremely high surface-area-to-volume ratio of the nanofiber mat results in near-instantaneous dissolution (<5 seconds) upon contact with saliva, leading to a rapid release of the prodrug for absorption. The trifluoroacetate ester groups are chosen for their rapid hydrolysis rate due to the strong electron-withdrawing effect of fluorine.

• Mermaid Diagram:

  classDiagram
    class Nanofiber {
      +diameter: 100-500 nm
      +dissolutionTime: < 5s
    }
    class Core {
      +material: Soluplus®
      +payload: Epinephrine Trifluoroacetate Prodrug
    }
    class Shell {
      +material: Pullulan or PVA
    }
    Nanofiber "1" -- "1" Core : contains
    Nanofiber "1" -- "1" Shell : is coated by
  

---

Section 2: Operational Parameter Expansion

Derivative 2.1: Lyophilized Cryo-Stable Film for Extreme Environments

• Enabling Description: A pharmaceutical formulation designed for stability in extreme temperature fluctuations (-80°C to +60°C), suitable for military or space exploration applications. The formulation begins as an aqueous solution of an epinephrine di-ester prodrug, a film-forming polymer (e.g., fish gelatin), and a cryoprotectant (e.g., trehalose at 10% w/v). This solution is cast into a mold and subjected to lyophilization (freeze-drying). The resulting dosage form is a highly porous, wafer-like film that is extremely low in residual water content (<1%), preventing degradation pathways. The trehalose forms a glassy matrix around the prodrug molecule, stabilizing its conformation. Reconstitution is instantaneous upon contact with saliva.

• Mermaid Diagram:

  flowchart TD
      A[Aqueous Solution: Prodrug, Gelatin, Trehalose] --> B{Freeze to -80°C};
      B --> C[Primary Drying: Sublimation under Vacuum];
      C --> D[Secondary Drying: Desorption of bound water];
      D --> E[Final Product: Porous Lyophilized Wafer];
      E -- Contact w/ Saliva --> F(Instant Dissolution & Drug Release);
  

Derivative 2.2: Nanoparticle-in-Film System for Pediatric Dosing

• Enabling Description: A system for delivering precise, weight-based pediatric doses of epinephrine. The epinephrine prodrug is first encapsulated in solid lipid nanoparticles (SLNs) with a mean diameter of 200 nm, using Compritol® 888 ATO as the lipid matrix. These SLNs are then suspended in a film-forming solution containing sodium alginate. The resulting film is cast and dried. The final product is a large film sheet that is homogenous in its distribution of SLNs. A pharmacist or caregiver can cut the film to a precise size/weight corresponding to the pediatric patient's body weight, with the dose being directly proportional to the area of the film segment. The lipid encapsulation provides an additional taste-masking layer.

• Mermaid Diagram:

  graph LR
      subgraph Manufacturing
          A(Epinephrine Prodrug) --> B(Melted Compritol® 888);
          B --> C{High-Shear Homogenization};
          C --> D[Solid Lipid Nanoparticles];
      end
      subgraph Compounding
          D --> E(Sodium Alginate Solution);
          E --> F{Solvent Casting & Drying};
      end
      F --> G[Homogenous Drug-in-SLN Film Sheet];
      G -- Cut to Size --> H(Precise Pediatric Dose);
  

---

Section 3: Cross-Domain Applications

Derivative 3.1: AgTech - Foliar Delivery of Systemic Fungicide Prodrug

• Enabling Description: A method for delivering a systemic fungicide to agricultural crops. The active fungicide, azoxystrobin, is chemically modified into a di-ester prodrug to enhance its permeability through the waxy leaf cuticle. This prodrug is incorporated into a rapidly dissolving film made of pectin and a surfactant (e.g., Tween 20). The film is applied to the leaf surface. Upon contact with moisture (dew or irrigation), the film dissolves, and the lipophilic prodrug is absorbed by the leaf. Plant-native esterase enzymes cleave the ester bonds, releasing the active azoxystrobin systemically throughout the plant's vascular system for protection against fungal pathogens.

• Mermaid Diagram:

  sequenceDiagram
      participant A as Film on Leaf
      participant B as Leaf Cuticle
      participant C as Plant Vascular System
      A->>B: Film dissolves with moisture, releases Prodrug
      B->>B: Lipophilic prodrug permeates waxy cuticle
      B->>C: Prodrug enters plant tissue
      C->>C: Plant esterases cleave prodrug
      C->>C: Active Azoxystrobin is released systemically
  

Derivative 3.2: Aerospace - Zero-G Delivery of Anti-Kinetosis Agent

• Enabling Description: A sublingual film for delivering scopolamine to astronauts to counteract space adaptation syndrome. Scopolamine is formulated as a quaternary ammonium prodrug to improve stability and modify its absorption profile. The prodrug is embedded in a fast-dissolving film of pullulan. The film is administered sublingually and dissolves without the need for water, which is a key advantage in a zero-gravity environment. Rapid onset of action is achieved by bypassing first-pass metabolism, allowing for effective management of nausea and disorientation during critical mission phases.

• Mermaid Diagram:

  stateDiagram-v2
      [*] --> Inactive: Astronaut is asymptomatic
      Inactive --> Active: Onset of Kinetosis Symptoms
      Active --> AdministerFilm: Sublingual Scopolamine Prodrug Film
      AdministerFilm --> Absorption: Rapid dissolution, no water needed
      Absorption --> TherapeuticEffect: Prodrug converts, symptoms abate
      TherapeuticEffect --> Inactive: Return to asymptomatic state
  

---

Section 4: Integration with Emerging Technology

Derivative 4.1: AI-Driven Closed-Loop Anaphylaxis Response System

• Enabling Description: A closed-loop system for automated anaphylaxis management. The system consists of: (1) a wearable sensor (e.g., a smartwatch with integrated electrochemical sensors) that continuously monitors for biomarkers of anaphylaxis in sweat, such as histamine. (2) A cloud-based AI algorithm that analyzes the sensor data to predict the onset of a systemic allergic reaction. (3) An IoT-enabled dispenser, worn by the user, containing a cartridge of epinephrine prodrug films. Upon positive detection by the AI, the cloud service sends a signal to the dispenser, which automatically dispenses a film into the user's mouth. The event, including sensor data and time of administration, is logged to a secure health record.

• Mermaid Diagram:

  flowchart TD
      A[Wearable Sensor] -- Histamine Data --> B(Cloud AI Platform);
      B -- Analyzes Risk --> C{Anaphylaxis Predicted?};
      C -- Yes --> D[Signal to IoT Dispenser];
      D --> E(Dispense Epinephrine Prodrug Film);
      E --> F[Patient Administers Film];
      C -- No --> B;
      D -- Log Event --> G[Blockchain Health Record];
  

---

Section 5: The "Inverse" or Failure Mode

Derivative 5.1: Biphasic Release Film for Acute and Sustained Action

• Enabling Description: A single dosage form designed to prevent biphasic anaphylactic reactions. The film is constructed with two layers. Layer 1 is a rapidly dissolving formulation (using sodium starch glycolate as a superdisintegrant) containing a 0.3 mg equivalent dose of an epinephrine prodrug for immediate treatment. Layer 2 is a mucoadhesive, slow-eroding layer (using Carbopol 971P and HPMC) containing a lower, 0.15 mg equivalent dose of the same prodrug. After the first layer dissolves and provides the initial bolus, the second layer adheres to the buccal mucosa and slowly erodes over 1-2 hours, releasing a sustained, low level of epinephrine to suppress the potential second wave of symptoms.

• Mermaid Diagram:

  graph TD
      subgraph Time=0-2 min
          A[Layer 1: Rapid Dissolution] --> B(High Plasma Epinephrine);
      end
      subgraph Time=2-120 min
          C[Layer 2: Slow Erosion] --> D(Sustained Low-Level Epinephrine);
      end
      Start --> A;
      A --> C;
      B --> E{Acute Symptom Resolution};
      D --> F{Prevention of Biphasic Reaction};
  

---

Section 6: Combination Prior Art with Open-Source Standards

1. Combination with HL7 FHIR: The AI-driven closed-loop system (Derivative 4.1) will log each automated administration event by creating an MedicationAdministration resource compliant with the HL7 FHIR (v4.0.1) standard. The resource will be populated with a medicationCodeableConcept specifying the epinephrine prodrug, a dosage element detailing the film strength, and an effectiveDateTime timestamp. This resource will be pushed to the patient's designated EHR via a secure API, ensuring interoperability with clinical decision support systems.

2. Combination with OPC UA: The manufacturing line for the Biphasic Release Film (Derivative 5.1) will be modeled using the OPC UA framework. The dual-layer casting machine's parameters (e.g., Layer 1 pump speed, Layer 2 viscosity, dryer temperature profile) are exposed as OPC UA variables. A Manufacturing Execution System (MES) subscribes to these variables for real-time monitoring and recipe management, and generates an electronic batch record that is compliant with the ISA-88 standard, using OPC UA as the underlying communication protocol.

3. Combination with W3C Verifiable Credentials: To ensure the authenticity of the Lyophilized Cryo-Stable Film (Derivative 2.1) for institutional buyers like space agencies or militaries, the manufacturer will issue a W3C Verifiable Credential for each batch. This digital credential, signed by the manufacturer's decentralized identifier (DID), will contain claims asserting the batch number, expiration date, and successful completion of stability testing at specified extreme temperatures. This allows a receiving entity to cryptographically verify the product's provenance and quality specifications without relying on a centralized database.